Novel Approach to Improve Immunotherapy Efficacy while Mitigating Side Effects of Alzheimer's Disease. An Experimental Approach.
Our study elucidated that FUS-mediated delivery of a low dose of lecanemab (1 mg/kg) decreases amyloid deposits and attenuates cognitive function deficits. We present an AD treatment strategy through the synergistic effect of the combined therapy of FUS and lecanemab.
Authors
- Eun‐Jeong Yang
- Giulio Maria Pasinetti (ORCID: https://orcid.org/0000-0002-1524-5196)
- Nicole Less
Institutions
- James J. Peters VA Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_107233
- Primary Topic
- Advanced Drug Delivery Systems
- Type
- article
- Field-Weighted Citation Impact
- 0.00